Cellectar Biosciences reported a third quarter 2026 net loss of $8.0 million, matching analyst earnings per share estimates. The company is prioritizing its lead candidate, iopofosine I 131, confirming plans for a New Drug Application submission in the first half of 2027 and a confirmatory Phase 3 trial start in early 2027. Clinical data presented during the quarter showed an 87.5% overall response rate in heavily pretreated Waldenström macroglobulinemia patients, supporting the proposed accelerated approval pathway.
Key Highlights
- Research and development expenses increased to $5.4 million from $2.5 million year-over-year, primarily due to Phase 3 trial activation costs.
- Cash and cash equivalents reached $24.6 million as of September 30, 2026, which management expects will fund operations into the second quarter of 2027.
- Confirmatory Phase 3 trial dosing for Waldenström macroglobulinemia is on schedule for the first quarter of 2027 with activation of initial clinical sites already underway.